Jennifer King, MD
Hematology & Oncology · Indianapolis, INNPI 1093163347
Payments from drug & device makers
What this record shows
This record is dominated by education: $481 of the $523 with a category attached, or 92.0%. 5 manufacturers reported payments, led by Seagen Inc. at 38.2% of the total. Reporting peaked in 2024 at $220 and has fallen 91.6% since, to $19 in 2025. That places this record below the midpoint for hematology & oncology clinicians in IN, where the typical reported total is $3,829.
Across 9 payments — averaging $58.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Seagen Inc.$200
- Eisai Inc.$197
- Sanofi-aventis U.S. LLC$85
- Boehringer Ingelheim$23
- Novartis$19
Across 23 payments — averaging $13,622 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Exelixis Inc.$232K
- Biontech SE$45K
- Gilead$36K
What the payments were for
- Food & beverage$428%
- Education$48192%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Seagen Inc. | 2 | $200 |
| Eisai Inc. | 4 | $197 |
| Sanofi-aventis U.S. LLC | 1 | $85 |
| Boehringer Ingelheim | 1 | $23 |
| Novartis | 1 | $19 |
How this compares
$523 in reported general payments places this provider in the 20th percentile of 224 hematology & oncology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CabometyxCabozantinib S-Malate | 18 | $427,163 |
| XtandiEnzalutamide | 17 | $228,536 |
| ErleadaApalutamide | 12 | $179,239 |
| Abiraterone Acetate | 113 | $168,108 |
| EliquisApixaban | 11 | $7,386 |
| XareltoRivaroxaban | 11 | $5,920 |
| Prednisone | 181 | $854 |
| Olanzapine | 20 | $469 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 17 | $321 |
| Ondansetron Hcl | 35 | $307 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 13 | $298 |
| Hydrocortisone | 13 | $250 |
| Gabapentin | 22 | $244 |
| Oxycodone Hcl | 18 | $154 |
| Levothyroxine Sodium | 20 | $140 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Indianapolis
- Richard GaynorIndianapolis$3.7M
- Ruemu BirhirayIndianapolis$3.1M
- Anand TandraIndianapolis$280K
- Attaya SuvannasankhaIndianapolis$253K
- Michael DuganIndianapolis$236K
- Daniel MiltonIndianapolis$231K
- Amro ElshouryIndianapolis$212K
- Brian MulherinIndianapolis$175K
- Muhammad Sarfraz NawazIndianapolis$172K
- John EdwardsIndianapolis$169K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.